• Net Revenue: $46 million in Q4 2024, compared to $47.3 million in Q4 2023.
• Device Revenue: $14.8 million in Q4 2024, down from $16.3 million in Q4 2023.
• Supplies Revenue: $31.2 million in Q4 2024, up from $31 million in Q4 2023.
• Gross Profit: $36 million or 78% of revenue in Q4 2024, compared to $37 million or 78% in Q4 2023.
• Sales and Marketing Expenses: $19.3 million in Q4 2024, down from $21.7 million in Q4 2023.
• G&A Expenses: $17.3 million in Q4 2024, up from $13 million in Q4 2023.
• Net Loss: $615,000 or $0.02 per share in Q4 2024, compared to net income of $1.2 million or $0.04 per share in Q4 2023.
• Adjusted EBITDA: $584,000 in Q4 2024, compared to $9.9 million in Q4 2023.
• Cash Flows from Operations: $2.4 million in Q4 2024 and $12.7 million for the full year.
• Cash Balance: $39.6 million at the end of Q4 2024, up 5% from Q3's balance of $37.6 million.
• Working Capital: $58.3 million as of December 31, 2024.
• Sales Force: Reduced from approximately 475 to 330 people by the end of 2024.
• Revenue per Sales Rep: Increased 22% to $490,000 on average in 2024.
• Projected Q1 2025 Revenue: Approximately $30 million.
• Projected Q1 2025 Net Loss: Between $9 million and $10 million.

• Warning! GuruFocus has detected 4 Warning Signs with ZYXI.

Release Date: March 11, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Zynex Inc (NASDAQ:ZYXI) reported a 4% increase in revenue for 2024, with order growth of 16% for the year.
• The company has diversified its revenue streams by adding new products, including internally developed and private label products.
• Positive test results for the NiCO pulse oximeter were received from trials at Duke University and the University of California, San Francisco.
• Zynex Inc (NASDAQ:ZYXI) has restructured its sales force, resulting in a 22% increase in revenue per sales representative.
• The company has a strong cash position with $39.6 million on the balance sheet, up 5% from the previous quarter.

Negative Points

• TRICARE has temporarily suspended payments to Zynex Inc (NASDAQ:ZYXI), affecting 20% to 25% of the company's revenue.
• The company reported a net loss of $615,000 in Q4 2024 compared to a net income of $1.2 million in Q4 2023.
• Adjusted EBITDA for Q4 2024 was significantly lower at $584,000 compared to $9.9 million in Q4 2023.
• The FDA submission for the NiCO pulse oximeter has been delayed into 2025, impacting potential revenue generation.
• Zynex Inc (NASDAQ:ZYXI) has reduced its workforce by 15%, primarily affecting corporate office employees, to manage costs amid revenue uncertainties.

Q & A Highlights

Q: Could you give us a sense of what was accomplished in the fourth quarter regarding the 15% staff reduction and how it will affect your OpEx lines? A: Daniel Moorhead, CFO, explained that less than half of the $30 million-plus in annual savings was achieved during 2024, with the rest implemented in Q1 2025. Sales expenses are expected to decrease by $1-2 million, and G&A expenses will also see a similar reduction.

Q: Could you elaborate on the commercial path to market for the NiCO pulse oximeter? A: Donald Gregg, President of Zynex Monitoring Solutions, stated that they are considering multiple strategies, including direct sales, partnerships, and indirect sales through 1099 organizations. They are prepared to execute these plans upon FDA clearance.

Q: What was the nature of the 2022 audit by TRICARE related to billing practices, and why didn't you have visibility into TRICARE's actions? A: Anna Lucsok, COO, mentioned that the audit was a routine post-payment audit with standard adjustments. The lack of visibility into TRICARE's recent actions is due to unclear communication from TRICARE regarding specific issues.

Q: Why don't you have visibility into sales for 2025, given that 75% of your business is still being reimbursed? A: Thomas Sandgaard, CEO, explained that the uncertainty with TRICARE, which represents a significant portion of revenue, makes it difficult to provide guidance. They are confident in resolving the issue but are taking a conservative approach until more clarity is obtained.

Q: What is your plan for the April meeting with TRICARE, and have they requested specific information? A: Anna Lucsok, COO, stated that TRICARE has provided vague guidance, but Zynex plans to present data on compliance with policies and refer to the 2022 audit findings. They aim to clarify and resolve the issues during the meeting.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.